Opinion|Videos|July 11, 2024
Exploring Biomarker Testing and Personalized Treatments in Breast Cancer
William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.
Advertisement
Episodes in this series
- What are the current guidelines for testing for targetable mutations in breast cancer, and how widely are they followed in clinical practice? How can biomarker testing for targetable mutations, such as PIK3CA or AKT1, be improved or streamlined?
- How accessible are these biomarker tests in community oncology?
- How is personalized medicine expected to impact the future use of targeted therapies (such as the PI3K pathway inhibitors) in breast cancer? What developments are needed to fully realize its potential?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Novel CLL Therapies Prompt New Treatment Considerations
2
Congress Unveils Massive Funding Bill to Avert Shutdown
3
Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma
4
Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma
5
